Table 4:

Associations between SHS exposure (defined as measured plasma cotinine >0.05 ng/mL or above the limit of quantification if higher than 0.05 ng/mL) and asthma outcomes by study (as proxy for race/ethnicity) using multiple imputation data to account for missing NMR values.

Asthma outcomes	OR (95% CI)
	Study
	GALA II	SAGE II
Asthma exacerbations in the previous 12 months*	1.38 (0.95 – 2.01)	1.27 (0.74 – 2.19)
Asthma control (binary outcome)†	1.27 (0.84 – 1.91)	2.16 (1.27 – 3.67)
Not well controlled vs controlled	1.21 (0.66 – 2.22)	1.58 (0.87 – 2.91)
Very poorly controlled vs controlled	1.33 (0.80 – 2.22)	2.77 (1.51 – 5.00)

^*Asthma exacerbations assessed as a combined variable for any exacerbations (hospitalizations, ER visits, prescription of oral steroids) vs none

^†Asthma control assessed as binary outcome with a combined “not well controlled” and “very poorly controlled” category compared to controlled asthma